Key Highlights
- DXCM shares are trading up 12.29% today to $83.58, up from a prior close of $74.54.
- Q2 revenue of $1.31 billion beat estimates, up 13% year-over-year, with adjusted EPS of $0.70 topping the $0.61 consensus by 15%.
- Operating margin expanded sharply to 24.3% from 18.4% a year earlier, and the company raised full-year 2026 revenue guidance to $5.18-$5.25 billion.
- More than a dozen firms, including Baird, Piper Sandler, Stifel, Evercore ISI, Mizuho, Truist, Deutsche Bank and RBC, raised price targets following the results.
Strong CGM Demand Drives Q2 Beat
DexCom, Inc. (NASDAQ:DXCM) shares are surging near 52-week highs today, up roughly 12%, after the company reported strong second-quarter 2026 results with revenue of $1.31 billion, up 13% year-over-year, beating estimates, and adjusted EPS of $0.70 topping the $0.61 consensus by 15%. DexCom, headquartered in San Diego, California and founded in 1999, is a medical technology company that commercializes continuous glucose monitoring systems for diabetes management and metabolic health, with a product portfolio including the Dexcom G6, G7 and G7 15 Day integrated CGM systems.
Operating margin expanded sharply to 24.3% from 18.4% a year earlier, and management raised full-year 2026 revenue guidance to $5.18-$5.25 billion while lifting margin outlooks, citing strong CGM demand, G7 15-day rollout momentum, and positive CONNECT clinical trial data in type 2 diabetes patients not on insulin.
Wave of Analyst Upgrades and Expanded Coverage
DexCom carries a market capitalization of approximately $32.30 billion, with shares trading at a forward price-to-earnings ratio of 20.30 and a trailing multiple of 35.92. The stock's 52-week range spans $54.11 to $84.70.
The results triggered a wave of bullish analyst actions, with over a dozen firms including Baird, Piper Sandler, Stifel, Evercore ISI, Mizuho, Truist, Deutsche Bank and RBC raising price targets, ranging roughly $82-$105, while maintaining Buy or Outperform ratings. RBC also flagged that an upcoming national coverage determination for DexCom's over-the-counter CGM system could support further H2 upside, as the company targets converting nearly 50% of its US installed base by year-end.
The company achieved coverage for all people with diabetes across the four largest commercial pharmacy benefit managers for its non-insulin population, with G7 15-Day rollout on track for roughly 50% of its US customer base by year-end. DexCom also launched Dexcom Flex in Germany, received Health Canada clearance for G7 15-Day, and completed the Nutrisense acquisition, a CGM-based nutrition insights platform, with immaterial incremental non-CGM revenue impact on current guidance.
Conclusion
DexCom's sharp rally reflects genuine strength across its core CGM business, reinforced by expanding margins, raised guidance and broad-based analyst support following the print. With a potential national coverage determination for its over-the-counter system still pending and the G7 15-Day rollout continuing to scale, investors will be watching whether the company can sustain this growth trajectory into the back half of 2026.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...